ClinicalTrials.gg
CompletedNCT00322465Updated Aug 27, 2026Results posted

NGU: Doxycycline (Plus or Minus Tinidazole) Versus Azithromycin (Plus or Minus Tinidazole)

A Phase 2 interventional study of Doxycycline and Placebo in Urethritis, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Completed at 4 sites in United States. Open to male participants aged 16 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
305
Allocation
Randomized
Ages
16 Years to 45 Years
Sex
Male
01

Study summary

This study will look at the safety, effectiveness, and tolerability of combination medications for the initial treatment of non-gonococcal urethritis (NGU). NGU is inflammation of the tube that carries urine from the bladder. NGU is caused by bacteria that may be passed from person to person during sex. This study will compare the 2 currently recommended NGU treatments, doxycycline and azithromycin, taken with tinidazole (another medication to treat certain sexually transmitted infections). Tinidazole used with doxycycline or azithromycin may cure NGU better than when doxycycline or azithromycin is used alone. Study participants will be 300 men ages 16-45 years with NGU attending sexually transmitted disease clinics in Birmingham, AL; New Orleans, LA; Durham, NC; and Baltimore, MD. Study participation will last 7 weeks and involve 3 visits. At each visit, participants will provide a urine sample, have 2 urethral swabs, and have their urethra checked for discharge indicating infection.

Read the detailed description

This study represents a clinical evaluation of the use of combination therapy for the initial treatment of non-gonococcal urethritis (NGU). This study will provide more current data on the comparison of cure rates between the 2 currently recommended therapies for NGU, doxycycline and azithromycin. Emerging clinical data has suggested that the latter may have become more efficacious for NGU as it is more effective in eradicating Mycoplasma (M.) genitalium from the genital tract than the former. Only in vitro data, limited as it is, suggests that doxycycline should be active against M. genitalium. The researchers hypothesize that cure rates for NGU will be significantly improved for both doxycycline and azithromycin using combination therapy with tinidazole. Important safety and tolerability data will be collected with regards to the use of combination therapy. Additionally, the study will provide data on the prevalence of the targeted pathogens in 4 geographic areas and on characteristics of men with NGU that may help to target populations who would benefit the most from combination therapy. The researchers hypothesize that currently recommended initial therapies for NGU are inadequate in at least certain populations due to lack of coverage for Trichomonas (T.) vaginalis. The researchers further hypothesize that between the 2 currently recommended regimens, azithromycin will result in a greater number of cures than doxycycline due to its greater efficacy in M. genitalium infected men. The primary study objectives are to: compare the clinical cure rates of doxycycline versus doxycycline with tinidazole; and azithromycin versus azithromycin with tinidazole for the treatment of NGU; and to evaluate the safety and tolerability of doxycycline/tinidazole and azithromycin/tinidazole in the treatment of NGU. Secondary study objectives are to: evaluate microbiological cure of Chlamydia (C.) trachomatis, T. vaginalis, M. genitalium in men treated with doxycycline versus doxycycline with tinidazole; and azithromycin versus azithromycin with tinidazole. Analysis will also include: (doxycycline plus doxycycline/tinidazole) versus (azithromycin plus azithromycin/tinidazole); for the clinical cure rates, analysis will also include: (doxycycline plus doxycycline/tinidazole) versus (azithromycin plus azithromycin/tinidazole); determine the prevalence of C. trachomatis, T. vaginalis, and M. genitalium in the study population of men with non-gonococcal urethritis; determine clinical, behavioral, and demographic predictors of the above organisms in men with non-gonococcal urethritis; and collect specimens for future studies to determine the role of unique and novel pathogens in the etiology of non-gonococcal urethritis. Outcome measures include clinical failure, clinical cure, microbiological cure, and unevaluable cure assessed at the first and second follow-up visits. Study participants will include 300 men ages 16-45 years with NGU attending sexually transmitted disease clinics in Birmingham, AL; New Orleans, LA; Durham, NC; and Baltimore, MD. Subjects will be randomly assigned to 1 of 4 active treatment arms: 75 subjects doxycycline; 75 subjects doxycycline plus tinidazole; 75 subjects azithromycin; and 75 subjects azithromycin plus tinidazole.

02

Conditions studied

  • Urethritis

Keywords

  • azithromycin
  • doxycycline
  • non-gonococcal urethritis
  • sexually transmitted
  • tinidazole
03

In context

Lead sponsor

National Institute of Allergy and Infectious Diseases (NIAID) is the lead sponsor of 2,449 studies on the registry; 181 are open to participants now.

Of its 406 completed or terminated interventional studies of FDA-regulated products, 303 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male, 16 to 45 years old.
  • Symptoms of non-gonococcal urethritis (NGU), including urethral discharge and/or dysuria for less than or equal to 14 days, or urethral discharge on exam.
  • Urethral smear with greater than or equal to 5 polymorphonuclear leukocytes (PMNs) per 3-5 oil immersion fields.
  • Willing to abstain from sexual intercourse or use condoms during the study.
  • Willingness to provide written consent.

Exclusion criteria

Exclusion Criteria:

  • Presence of gonorrhea at baseline visit.
  • History of recurrent non-gonococcal urethritis (NGU) (3 or more episodes in the prior year) or history of recent NGU (within past 30 days).
  • Signs or symptoms of epididymitis or prostatitis.
  • Known allergy to or intolerance of tinidazole, tetracyclines, macrolides or metronidazole.
  • History of photosensitivity related to doxycycline use.
  • Received systemic antibiotics within 30 days of study enrollment.
  • Unwillingness to abstain from alcohol for 24 hours after enrollment.
  • Serious underlying infection, including known or other primary or secondary .
  • Concomitant infection, which requires antimicrobial therapy.
  • History of mental illness, which would preclude responsible participation in the study.
  • Current drug abuse that might affect ability to follow the protocol.
  • Previously enrolled in this study.
  • Men who have sex with men, due to different microbiology of NGU.
  • Voided within the previous hour.
  • Ingested alcohol within the past 8 hours.
  • Subject requires concurrent lithium, anticoagulation therapy, or antabuse.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
305 participants (actual)

Study arms

  • Experimental
    Azithromycin

    Azithromycin 1 gram (gm) orally single dose (2 tablets at 500 milligrams (mg) each) plus doxycycline placebo twice daily for 7 days plus tinidazole placebo single dose.

    Other: Placebo · Drug: Azithromycin

  • Experimental
    Azithromycin + Tinidazole

    Azithromycin 1 gm orally single dose (2 tablets at 500 mg each) plus doxycycline placebo twice daily for 7 days plus tinidazole single dose (4 tablets at 500 mg each).

    Other: Placebo · Drug: Tinidazole · Drug: Azithromycin

  • Experimental
    Doxycycline

    Doxycycline 100 mg orally twice daily (2 pills/day = 200 mg/day) for 7 days plus placebo azithromycin orally single dose and placebo tinidazole.

    Drug: Doxycycline · Other: Placebo

  • Experimental
    Doxycycline + Tinidazole

    Doxycycline 100 mg orally twice daily for 7 days plus placebo azithromycin single dose plus tinidazole 2 gm orally single dose (4 tablets at 500 mg each).

    Drug: Doxycycline · Other: Placebo · Drug: Tinidazole

Interventions

  • 100 mg orally, twice daily for 7 days.

  • OtherPlacebo

    Placebo capsule will be filled with lactose only and be identical in appearance to the capsule of Azithromycin, Tinidazole, Doxycycline.

  • 2 gm single dose (4 tablets orally at 500 mg each).

  • 1 gram (gm) (2 tablets orally at 500 milligrams (mg) each)

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability of Doxycycline/Tinidazole and Azithromycin/Tinidazole: Number of Participants Reporting Nausea

    At all study visits, unsolicited adverse events were recorded. Nausea, Vomiting, Abdominal pain, and Diarrhea were recorded using National Cancer Institute Common Toxicity Criteria (Version 3.0).

    Time frame: First follow-up visit (Day 15-19), second follow-up visit (Day 35-45)

  2. Safety and Tolerability of Doxycycline/Tinidazole and Azithromycin/Tinidazole: Number of Participants Reporting Vomiting

    At all study visits, unsolicited adverse events were recorded. Nausea, Vomiting, Abdominal pain, and Diarrhea were recorded using National Cancer Institute Common Toxicity Criteria (Version 3.0).

    Time frame: First follow-up visit (Day 15-19), second follow-up visit (Day 35-45)

  3. Safety and Tolerability of Doxycycline/Tinidazole and Azithromycin/Tinidazole: Number of Participants Reporting Stomach Upset

    At all study visits, unsolicited adverse events were recorded.

    Time frame: First follow-up visit (Day 15-19), second follow-up visit (Day 35-45)

  4. Safety and Tolerability of Doxycycline/Tinidazole and Azithromycin/Tinidazole: Number of Participants Reporting of Abdominal Pain

    At all study visits, unsolicited adverse events were recorded. Nausea, Vomiting, Abdominal pain, and Diarrhea were recorded using National Cancer Institute Common Toxicity Criteria (Version 3.0).

    Time frame: First follow-up visit (Day 15-19), second follow-up visit (Day 35-45)

  5. Safety and Tolerability of Doxycycline/Tinidazole and Azithromycin/Tinidazole: Number of Participants Reporting Diarrhea

    At all study visits, unsolicited adverse events were recorded. Nausea, Vomiting, Abdominal pain, and Diarrhea were recorded using National Cancer Institute Common Toxicity Criteria (Version 3.0).

    Time frame: First follow-up visit (Day 15-19), second follow-up visit (Day 35-45)

  6. Percentage of Participants Achieving Clinical Cure of Non-gonococcal Urethritis (NGU) With Doxycycline Versus Doxycycline With Tinidazole; and Azithromycin Versus Azithromycin With Tinidazole

    Clinical Cure of NGU: Did not meet criteria for clinical failure at last evaluable follow-up visit. Clinical Failure at first follow-up: \[Persistent symptoms AND \>= 5 polymorphonuclear leukocytes (PMNs) per 3-5 oil immersion fields (regardless of urethral discharge)\] OR Persistent urethral discharge on exam (regardless of symptoms or number of PMNs). Clinical Failure at second follow-up: \>= 5 PMNs per 3-5 oil immersion fields (regardless of symptoms or presence of urethral discharge) OR Persistent urethral discharge on exam (regardless of symptoms or number of PMNs)

    Time frame: First follow-up visit (Day 15-19), second follow-up visit (Day 35-45)

Secondary outcomes

  1. Percentage of Participants Achieving Clinical Cure of NGU With (Doxycycline Plus Doxycycline/Tinidazole) Versus (Azithromycin Plus Azithromycin/Tinidazole)

    Clinical Cure of NGU: Did not meet criteria for clinical failure at last evaluable follow-up visit. Clinical Failure at first follow-up: \[Persistent symptoms AND \>= 5 PMNs per 3-5 oil immersion fields (regardless of urethral discharge)\] OR Persistent urethral discharge on exam (regardless of symptoms or number of PMNs). Clinical Failure at second follow-up: \>= 5 PMNs per 3-5 oil immersion fields (regardless of symptoms or presence of urethral discharge) OR Persistent urethral discharge on exam (regardless of symptoms or number of PMNs)

    Time frame: First follow-up visit (Day 15-19), second follow-up visit (Day 35-45)

  2. Percentage of Participants Achieving Microbiological Cure of Chlamydia Trachomatis With Doxycycline Versus Doxycycline With Tinidazole; and Azithromycin Versus Azithromycin With Tinidazole

    Microbiological cure of Chlamydia trachomatis refers to the percentage of men with NGU who were negative for Chlamydia trachomatis at the last available result and had been positive for Chlamydia trachomatis at baseline.

    Time frame: First follow-up visit (Day 15-19), second follow-up visit (Day 35-45)

  3. Percentage of Participants Achieving Microbiological Cure of Trichomonas Vaginalis With Doxycycline Versus Doxycycline With Tinidazole; and Azithromycin Versus Azithromycin With Tinidazole

    Microbiological cure of Trichomonas vaginalis refers to the percentage of men with NGU who were negative for Trichomonas vaginalis (swab and urine specimens) at the last available result and had been positive for Trichomonas vaginalis at baseline (swab or urine specimen).

    Time frame: First follow-up visit (Day 15-19), second follow-up visit (Day 35-45)

  4. Percentage of Participants Achieving Microbiological Cure of Mycoplasma Genitalium With Doxycycline Versus Doxycycline With Tinidazole; and Azithromycin Versus Azithromycin With Tinidazole

    Microbiological Cure of Mycoplasma Genitalium refers to the percentage of men with NGU who were negative for Mycoplasma Genitalium at the last available result and had been positive for Mycoplasma Genitalium at baseline.

    Time frame: First follow-up visit (Day 15-19), second follow-up visit (Day 35-45)

  5. Prevalence of Chlamydia Trachomatis in Men With Non-gonococcal Urethritis

    Percentage of men with non-gonococcal urethritis that had a positive result for Chlamydia trachomatis at baseline (enrollment)

    Time frame: Baseline (enrollment visit)

  6. Prevalence of Trichomonas Vaginalis (Swab or Urine Specimen) in Men With Non-gonococcal Urethritis

    Percentage of men with non-gonococcal urethritis that had a positive result for Trichomonas vaginalis from a urethral swab or urine specimen at baseline (enrollment)

    Time frame: Baseline (enrollment visit)

  7. Prevalence of Mycoplasma Genitalium in Men With Non-gonococcal Urethritis

    Percentage of men with non-gonococcal urethritis that had a positive result for Mycoplasma genitalium at baseline (enrollment)

    Time frame: Baseline (enrollment)

  8. Clinical, Behavioral, and Demographic Predictors of Chlamydia Trachomatis in Men With Non-gonococcal Urethritis

    Clinical, behavioral, and demographic variables considered were discharge amount and appearance; condom use last sex; new recent partner; number of partners and new partners in last 30 days as well as last 3 months; number of times vaginal sex, oral sex, or anal sex in past 30 days; always/almost always used condom in last 3 months.

    Time frame: Baseline (enrollment visit)

  9. Clinical, Behavioral, and Demographic Predictors of Trichomonas Vaginalis in Men With Non-gonococcal Urethritis

    Trichomonas vaginalis was determined from urethral swab or urine specimen. Clinical, behavioral, and demographic predictors considered included discharge amount and appearance; condom use last sex; new recent partner; number of partners and new partners in last 30 days and last 3 months; number of times vaginal sex, oral sex, or anal sex in last 30 days; always/almost always used condom in last 3 months.

    Time frame: Baseline (enrollment visit)

  10. Clinical, Behavioral, and Demographic Predictors of Mycoplasma Genitalium in Men With Non-gonococcal Urethritis

    Logistic multiple regression with independent variable selection based on single variable models with p\<0.10. Participants positive at enrollment for Mycoplasma genitalium from urine specimen. Potential variables: discharge amount and appearance; condom use last sex; new recent partner, number of partners and new partners in last 30 days and last 3 months; number of times vaginal sex, oral sex, or anal sex in last 30 days; always/almost always used condom last 3 months.

    Time frame: Baseline (enrollment visit)

  11. Specimens for Future Studies to Determine the Role of Unique and Novel Pathogens in the Etiology of Non-gonococcal Urethritis

    Urethral swabs and urine specimens collected at each study visit for future studies to determine the role of unique and novel pathogens in the etiology of non-gonococcal urethritis

    Time frame: Baseline (enrollment); First follow-up visit (Day 15-19), second follow-up visit (Day 35-45)

07

Results

Posted Aug 17, 2011

Participant flow

Participant flow — Overall Study
MilestoneDoxycyclineDoxycycline + TinidazoleAzithromycinAzithromycin + Tinidazole
Started76737779
Completed56495153
Not completed20242626

Outcome measures

PrimarySafety and Tolerability of Doxycycline/Tinidazole and Azithromycin/Tinidazole: Number of Participants Reporting Nausea

At all study visits, unsolicited adverse events were recorded. Nausea, Vomiting, Abdominal pain, and Diarrhea were recorded using National Cancer Institute Common Toxicity Criteria (Version 3.0).

Time frame:
First follow-up visit (Day 15-19), second follow-up visit (Day 35-45)
Reported as:
Number · Participants
Safety and Tolerability of Doxycycline/Tinidazole and Azithromycin/Tinidazole: Number of Participants Reporting Nausea
ParticipantsDoxycyclineDoxycycline + TinidazoleAzithromycinAzithromycin + Tinidazole
Safety and Tolerability of Doxycycline/Tinidazole and Azithromycin/Tinidazole: Number of Participants Reporting Nausea3404
PrimarySafety and Tolerability of Doxycycline/Tinidazole and Azithromycin/Tinidazole: Number of Participants Reporting Vomiting

At all study visits, unsolicited adverse events were recorded. Nausea, Vomiting, Abdominal pain, and Diarrhea were recorded using National Cancer Institute Common Toxicity Criteria (Version 3.0).

Time frame:
First follow-up visit (Day 15-19), second follow-up visit (Day 35-45)
Reported as:
Number · Participants
Safety and Tolerability of Doxycycline/Tinidazole and Azithromycin/Tinidazole: Number of Participants Reporting Vomiting
ParticipantsDoxycyclineDoxycycline + TinidazoleAzithromycinAzithromycin + Tinidazole
Safety and Tolerability of Doxycycline/Tinidazole and Azithromycin/Tinidazole: Number of Participants Reporting Vomiting4200
PrimarySafety and Tolerability of Doxycycline/Tinidazole and Azithromycin/Tinidazole: Number of Participants Reporting Stomach Upset

At all study visits, unsolicited adverse events were recorded.

Time frame:
First follow-up visit (Day 15-19), second follow-up visit (Day 35-45)
Reported as:
Number · Participants
Safety and Tolerability of Doxycycline/Tinidazole and Azithromycin/Tinidazole: Number of Participants Reporting Stomach Upset
ParticipantsDoxycyclineDoxycycline + TinidazoleAzithromycinAzithromycin + Tinidazole
Safety and Tolerability of Doxycycline/Tinidazole and Azithromycin/Tinidazole: Number of Participants Reporting Stomach Upset1110
PrimarySafety and Tolerability of Doxycycline/Tinidazole and Azithromycin/Tinidazole: Number of Participants Reporting of Abdominal Pain

At all study visits, unsolicited adverse events were recorded. Nausea, Vomiting, Abdominal pain, and Diarrhea were recorded using National Cancer Institute Common Toxicity Criteria (Version 3.0).

Time frame:
First follow-up visit (Day 15-19), second follow-up visit (Day 35-45)
Reported as:
Number · Participants
Safety and Tolerability of Doxycycline/Tinidazole and Azithromycin/Tinidazole: Number of Participants Reporting of Abdominal Pain
ParticipantsDoxycyclineDoxycycline + TinidazoleAzithromycinAzithromycin + Tinidazole
Safety and Tolerability of Doxycycline/Tinidazole and Azithromycin/Tinidazole: Number of Participants Reporting of Abdominal Pain6535
PrimarySafety and Tolerability of Doxycycline/Tinidazole and Azithromycin/Tinidazole: Number of Participants Reporting Diarrhea

At all study visits, unsolicited adverse events were recorded. Nausea, Vomiting, Abdominal pain, and Diarrhea were recorded using National Cancer Institute Common Toxicity Criteria (Version 3.0).

Time frame:
First follow-up visit (Day 15-19), second follow-up visit (Day 35-45)
Reported as:
Number · Participants
Safety and Tolerability of Doxycycline/Tinidazole and Azithromycin/Tinidazole: Number of Participants Reporting Diarrhea
ParticipantsDoxycyclineDoxycycline + TinidazoleAzithromycinAzithromycin + Tinidazole
Safety and Tolerability of Doxycycline/Tinidazole and Azithromycin/Tinidazole: Number of Participants Reporting Diarrhea0337
PrimaryPercentage of Participants Achieving Clinical Cure of Non-gonococcal Urethritis (NGU) With Doxycycline Versus Doxycycline With Tinidazole; and Azithromycin Versus Azithromycin With Tinidazole

Clinical Cure of NGU: Did not meet criteria for clinical failure at last evaluable follow-up visit. Clinical Failure at first follow-up: \[Persistent symptoms AND \>= 5 polymorphonuclear leukocytes (PMNs) per 3-5 oil immersion fields (regardless of urethral discharge)\] OR Persistent urethral discharge on exam (regardless of symptoms or number of PMNs). Clinical Failure at second follow-up: \>= 5 PMNs per 3-5 oil immersion fields (regardless of symptoms or presence of urethral discharge) OR Persistent urethral discharge on exam (regardless of symptoms or number of PMNs)

Time frame:
First follow-up visit (Day 15-19), second follow-up visit (Day 35-45)
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Clinical Cure of Non-gonococcal Urethritis (NGU) With Doxycycline Versus Doxycycline With Tinidazole; and Azithromycin Versus Azithromycin With Tinidazole
Percentage of participantsDoxycyclineDoxycycline + TinidazoleAzithromycinAzithromycin + Tinidazole
Percentage of Participants Achieving Clinical Cure of Non-gonococcal Urethritis (NGU) With Doxycycline Versus Doxycycline With Tinidazole; and Azithromycin Versus Azithromycin With Tinidazole47 (40.8 to 64.2)51 (37.4 to 61.3)39 (49.3 to 72.0)48 (40.4 to 63.3)
SecondaryPercentage of Participants Achieving Clinical Cure of NGU With (Doxycycline Plus Doxycycline/Tinidazole) Versus (Azithromycin Plus Azithromycin/Tinidazole)

Clinical Cure of NGU: Did not meet criteria for clinical failure at last evaluable follow-up visit. Clinical Failure at first follow-up: \[Persistent symptoms AND \>= 5 PMNs per 3-5 oil immersion fields (regardless of urethral discharge)\] OR Persistent urethral discharge on exam (regardless of symptoms or number of PMNs). Clinical Failure at second follow-up: \>= 5 PMNs per 3-5 oil immersion fields (regardless of symptoms or presence of urethral discharge) OR Persistent urethral discharge on exam (regardless of symptoms or number of PMNs)

Time frame:
First follow-up visit (Day 15-19), second follow-up visit (Day 35-45)
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Clinical Cure of NGU With (Doxycycline Plus Doxycycline/Tinidazole) Versus (Azithromycin Plus Azithromycin/Tinidazole)
Percentage of participantsDoxycycline + (Doxycycline + Tinidazole)Azithromycin + (Azithromycin + Tinidazole)
Percentage of Participants Achieving Clinical Cure of NGU With (Doxycycline Plus Doxycycline/Tinidazole) Versus (Azithromycin Plus Azithromycin/Tinidazole)4944
SecondaryPercentage of Participants Achieving Microbiological Cure of Chlamydia Trachomatis With Doxycycline Versus Doxycycline With Tinidazole; and Azithromycin Versus Azithromycin With Tinidazole

Microbiological cure of Chlamydia trachomatis refers to the percentage of men with NGU who were negative for Chlamydia trachomatis at the last available result and had been positive for Chlamydia trachomatis at baseline.

Time frame:
First follow-up visit (Day 15-19), second follow-up visit (Day 35-45)
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Microbiological Cure of Chlamydia Trachomatis With Doxycycline Versus Doxycycline With Tinidazole; and Azithromycin Versus Azithromycin With Tinidazole
Percentage of participantsDoxycyclineDoxycycline + TinidazoleAzithromycinAzithromycin + Tinidazole
Percentage of Participants Achieving Microbiological Cure of Chlamydia Trachomatis With Doxycycline Versus Doxycycline With Tinidazole; and Azithromycin Versus Azithromycin With Tinidazole89756661
SecondaryPercentage of Participants Achieving Microbiological Cure of Trichomonas Vaginalis With Doxycycline Versus Doxycycline With Tinidazole; and Azithromycin Versus Azithromycin With Tinidazole

Microbiological cure of Trichomonas vaginalis refers to the percentage of men with NGU who were negative for Trichomonas vaginalis (swab and urine specimens) at the last available result and had been positive for Trichomonas vaginalis at baseline (swab or urine specimen).

Time frame:
First follow-up visit (Day 15-19), second follow-up visit (Day 35-45)
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Microbiological Cure of Trichomonas Vaginalis With Doxycycline Versus Doxycycline With Tinidazole; and Azithromycin Versus Azithromycin With Tinidazole
Percentage of participantsDoxycyclineDoxycycline + TinidazoleAzithromycinAzithromycin + Tinidazole
Percentage of Participants Achieving Microbiological Cure of Trichomonas Vaginalis With Doxycycline Versus Doxycycline With Tinidazole; and Azithromycin Versus Azithromycin With Tinidazole55755650
SecondaryPercentage of Participants Achieving Microbiological Cure of Mycoplasma Genitalium With Doxycycline Versus Doxycycline With Tinidazole; and Azithromycin Versus Azithromycin With Tinidazole

Microbiological Cure of Mycoplasma Genitalium refers to the percentage of men with NGU who were negative for Mycoplasma Genitalium at the last available result and had been positive for Mycoplasma Genitalium at baseline.

Time frame:
First follow-up visit (Day 15-19), second follow-up visit (Day 35-45)
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Microbiological Cure of Mycoplasma Genitalium With Doxycycline Versus Doxycycline With Tinidazole; and Azithromycin Versus Azithromycin With Tinidazole
Percentage of participantsDoxycyclineDoxycycline + TinidazoleAzithromycinAzithromycin + Tinidazole
Percentage of Participants Achieving Microbiological Cure of Mycoplasma Genitalium With Doxycycline Versus Doxycycline With Tinidazole; and Azithromycin Versus Azithromycin With Tinidazole23325268
SecondaryPrevalence of Chlamydia Trachomatis in Men With Non-gonococcal Urethritis

Percentage of men with non-gonococcal urethritis that had a positive result for Chlamydia trachomatis at baseline (enrollment)

Time frame:
Baseline (enrollment visit)
Reported as:
Number · Percentage of participants
Prevalence of Chlamydia Trachomatis in Men With Non-gonococcal Urethritis
Percentage of participantsDoxycyclineDoxycycline + TinidazoleAzithromycinAzithromycin + Tinidazole
Prevalence of Chlamydia Trachomatis in Men With Non-gonococcal Urethritis50383846
SecondaryPrevalence of Trichomonas Vaginalis (Swab or Urine Specimen) in Men With Non-gonococcal Urethritis

Percentage of men with non-gonococcal urethritis that had a positive result for Trichomonas vaginalis from a urethral swab or urine specimen at baseline (enrollment)

Time frame:
Baseline (enrollment visit)
Reported as:
Number · Percentage of participants
Prevalence of Trichomonas Vaginalis (Swab or Urine Specimen) in Men With Non-gonococcal Urethritis
Percentage of participantsDoxycyclineDoxycycline + TinidazoleAzithromycinAzithromycin + Tinidazole
Prevalence of Trichomonas Vaginalis (Swab or Urine Specimen) in Men With Non-gonococcal Urethritis14161210
SecondaryPrevalence of Mycoplasma Genitalium in Men With Non-gonococcal Urethritis

Percentage of men with non-gonococcal urethritis that had a positive result for Mycoplasma genitalium at baseline (enrollment)

Time frame:
Baseline (enrollment)
Reported as:
Number · Percentage of participants
Prevalence of Mycoplasma Genitalium in Men With Non-gonococcal Urethritis
Percentage of participantsDoxycyclineDoxycycline + TinidazoleAzithromycinAzithromycin + Tinidazole
Prevalence of Mycoplasma Genitalium in Men With Non-gonococcal Urethritis29303232
SecondaryClinical, Behavioral, and Demographic Predictors of Chlamydia Trachomatis in Men With Non-gonococcal Urethritis

Clinical, behavioral, and demographic variables considered were discharge amount and appearance; condom use last sex; new recent partner; number of partners and new partners in last 30 days as well as last 3 months; number of times vaginal sex, oral sex, or anal sex in past 30 days; always/almost always used condom in last 3 months.

Time frame:
Baseline (enrollment visit)
Reported as:
Number · Participants
Clinical, Behavioral, and Demographic Predictors of Chlamydia Trachomatis in Men With Non-gonococcal Urethritis
ParticipantsAll Participants Analyzed
Positive for Chlamydia Trachomatis at Baseline128
Negative for Chlamydia Trachomatis at Baseline162
Statistical analysis
  • All Participants Analyzed · Regression, Logistic · p = 0.005 (A priori threshold for statistical significance was p\<0.05.) · Odds ratio (or): 0.74 · 95% CI 0.60 to 0.91Odds ratio has been adjusted for other independent variables included in the model, which are found in the other Statistical Analysis sections.
  • All Participants Analyzed · Regression, Logistic · p = 0.780 (A priori threshold for statistical significance was p\<0.05.) · Odds ratio (or): 0.87 · 95% CI 0.33 to 2.30Odds ratio has been adjusted for other independent variables included in the model, which are found in the other Statistical Analysis sections.
  • All Participants Analyzed · Regression, Logistic · p = 0.164 (A priori threshold for statistical significance was p\<0.05.) · Odds ratio (or): 2.00 · 95% CI 0.75 to 5.33Odds ratio has been adjusted for other independent variables included in the model, which are found in the other Statistical Analysis sections.
  • All Participants Analyzed · Regression, Logistic · p = 0.919 (A priori threshold for statistical significance was p\<0.05.) · Odds ratio (or): 1.09 · 95% CI 0.23 to 5.17Odds ratio has been adjusted for other independent variables included in the model, which are found in the other Statistical Analysis sections.
  • All Participants Analyzed · Regression, Logistic · p = 0.051 (A priori threshold for statistical significance was p\<0.05.) · Odds ratio (or): 1.81 · 95% CI 1.00 to 3.30Odds ratio has been adjusted for other independent variables included in the model, which are found in the other Statistical Analysis sections.
  • All Participants Analyzed · Regression, Logistic · p = 0.076 (A priori threshold for statistical significance was p\<0.05) · Odds ratio (or): 4.42 · 95% CI 0.86 to 22.74Odds ratio has been adjusted for other independent variables included in the model, which are found in the other Statistical Analysis sections.
  • All Participants Analyzed · Regression, Logistic · p = 0.075 (A priori threshold fors tatistical significance was p\<0.05.) · Odds ratio (or): 0.38 · 95% CI 0.13 to 1.10Odds ratio has been adjusted for other independent variables included in the model, which are found in the other Statistical Analysis sections.
  • All Participants Analyzed · Regression, Logistic · p = <0.001 (A priori threshold for statistical significance was p\<0.05.) · Odds ratio (or): 3.92 · 95% CI 1.93 to 7.98Odds ratio has been adjusted for other independent variables included in the model, which are found in the other Statistical Analysis sections.
SecondaryClinical, Behavioral, and Demographic Predictors of Trichomonas Vaginalis in Men With Non-gonococcal Urethritis

Trichomonas vaginalis was determined from urethral swab or urine specimen. Clinical, behavioral, and demographic predictors considered included discharge amount and appearance; condom use last sex; new recent partner; number of partners and new partners in last 30 days and last 3 months; number of times vaginal sex, oral sex, or anal sex in last 30 days; always/almost always used condom in last 3 months.

Time frame:
Baseline (enrollment visit)
Reported as:
Number · Participants
Clinical, Behavioral, and Demographic Predictors of Trichomonas Vaginalis in Men With Non-gonococcal Urethritis
ParticipantsAll Participants Analyzed
Positive for Trichomonas Vaginalis at Baseline38
Negative for Trichomonas Vaginalis at Baseline253
Statistical analysis
  • All Participants Analyzed · Regression, Logistic · p = 0.009 (A priori threshold for statistical significance was p\<0.05.) · Odds ratio (or): 0.20 · 95% CI 0.06 to 0.66Odds ratio has been adjusted for other independent variables included in the model, which are found in the other Statistical Analysis sections.
  • All Participants Analyzed · Regression, Logistic · p = 0.074 (A priori threshold for statistical signficance was p\<0.05.) · Odds ratio (or): 2.39 · 95% CI 0.92 to 6.22Odds ratio has been adjusted for other independent variables included in the model, which are found in the other Statistical Analysis sections.
SecondaryClinical, Behavioral, and Demographic Predictors of Mycoplasma Genitalium in Men With Non-gonococcal Urethritis

Logistic multiple regression with independent variable selection based on single variable models with p\<0.10. Participants positive at enrollment for Mycoplasma genitalium from urine specimen. Potential variables: discharge amount and appearance; condom use last sex; new recent partner, number of partners and new partners in last 30 days and last 3 months; number of times vaginal sex, oral sex, or anal sex in last 30 days; always/almost always used condom last 3 months.

Time frame:
Baseline (enrollment visit)
Reported as:
Number · Participants
Clinical, Behavioral, and Demographic Predictors of Mycoplasma Genitalium in Men With Non-gonococcal Urethritis
ParticipantsAll Participants Analyzed
Positive for Mycoplasma Genitalium at Baseline90
Negative for Mycoplasma Genitalium at Baseline202
Statistical analysis
  • All Participants Analyzed · Regression, Logistic · p = 0.032 (A priori threshold for statistical significance was p\<0.05.) · Odds ratio (or): 0.80 · 95% CI 0.66 to 0.98No other independent variables were included in the model.
SecondarySpecimens for Future Studies to Determine the Role of Unique and Novel Pathogens in the Etiology of Non-gonococcal Urethritis

Urethral swabs and urine specimens collected at each study visit for future studies to determine the role of unique and novel pathogens in the etiology of non-gonococcal urethritis

Time frame:
Baseline (enrollment); First follow-up visit (Day 15-19), second follow-up visit (Day 35-45)
Reported as:
Number · specimens collected
Specimens for Future Studies to Determine the Role of Unique and Novel Pathogens in the Etiology of Non-gonococcal Urethritis
specimens collectedDoxycyclineDoxycycline + TinidazoleAzithromycinAzithromycin + Tinidazole
Specimens for Future Studies to Determine the Role of Unique and Novel Pathogens in the Etiology of Non-gonococcal Urethritis0000

Adverse events

Collected over Trial involved an enrollment visit, first follow-up visit (Day 15-19), and second follow-up visit (Day 35-45). Timeframe was approximately 7 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Doxycycline—0/76 (0%)18/76 (23.7%)
Doxycycline + Tinidazole—0/73 (0%)25/73 (34.2%)
Azithromycin—0/77 (0%)11/77 (14.3%)
Azithromycin + Tinidazole—0/79 (0%)24/79 (30.4%)
Most frequent other events
Showing 10 of 35
Most frequent other events
EventDoxycyclineDoxycycline + TinidazoleAzithromycinAzithromycin + Tinidazole
DiarrheaGastrointestinal disorders0/763/733/777/79
Taste abnormality/ disgeusiaNervous system disorders0/766/730/774/79
Abdominal painGastrointestinal disorders6/765/733/775/79
HeadacheNervous system disorders4/764/730/772/79
NauseaGastrointestinal disorders3/764/730/774/79
VomitingGastrointestinal disorders4/762/730/770/79
Light headedness/ dizzinessNervous system disorders0/760/730/772/79
Dry mouthGastrointestinal disorders1/761/730/770/79
DyspepsiaGastrointestinal disorders1/761/730/770/79
FatigueGeneral disorders0/761/730/770/79

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)DoxycyclineDoxycycline + TinidazoleAzithromycinAzithromycin + TinidazoleTotal
<=18 years11237
Between 18 and 65 years75727576298
>=65 years00000
Age, Continuous
Age, Continuous(years)DoxycyclineDoxycycline + TinidazoleAzithromycinAzithromycin + TinidazoleTotal
Mean27.3 ± 7.027.8 ± 6.826.4 ± 6.725.7 ± 7.226.8 ± 6.9
Sex: Female, Male
Sex: Female, Male(Participants)DoxycyclineDoxycycline + TinidazoleAzithromycinAzithromycin + TinidazoleTotal
Female00000
Male76737779305
Region of Enrollment
Region of Enrollment(participants)DoxycyclineDoxycycline + TinidazoleAzithromycinAzithromycin + TinidazoleTotal
United States76737779305
08

Study locations

4 sites
  • University of Alabama Hospital - Infectious Diseases
    Birmingham, Alabama 35249-0001, United States
  • Delgado Personal Health Center
    New Orleans, Louisiana 70112-3503, United States
  • Johns Hopkins Hospital - Emergency Department
    Baltimore, Maryland 21287-0010, United States
  • University of North Carolina School of Medicine - Center for Infectious Diseases
    Chapel Hill, North Carolina 27599-7030, United States
09

References and documents

Publications

  • Schwebke JR, Rompalo A, Taylor S, Sena AC, Martin DH, Lopez LM, Lensing S, Lee JY. Re-evaluating the treatment of nongonococcal urethritis: emphasizing emerging pathogens--a randomized clinical trial. Clin Infect Dis. 2011 Jan 15;52(2):163-70. doi: 10.1093/cid/ciq074. PubMed 21288838 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2006 to primary completion in Apr 2009, 29 months.

Results were first posted in Aug 2011, 2 years 3 months after primary completion. A results delay was requested in Jun 2010.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2006
First posted
May 8, 2006
StartActual
Nov 17, 2006
Primary completionActual
Apr 20, 2009
CompletionActual
Apr 20, 2009
Results delay requested
Jun 17, 2010
Results first posted
Aug 17, 2011
Last update
Aug 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00322465
Responsible party
Sponsor
First posted
May 8, 2006
Start date
Nov 17, 2006
Primary completion
Apr 20, 2009
Completion
Apr 20, 2009
Results posted
Aug 17, 2011
Last update
Aug 27, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Doxycycline · Tinidazole · Azithromycin

Start the discussion